Everolimus Shows Synergistic Antimyeloma Effects with Bortezomib via the AKT/mTOR Pathway. (January 2019)

• Record Type: Journal Article
• Authors: Li, Jing; Liu, Zhaoyun; Li, Yanqi; Jing, Qian; Wang, Honglei; Liu, Hui; Chen, Jin; Feng, Junru; Shao, Qing; Fu, Rong
• Is Part Of: Journal of investigative medicine. Volume 67:Number 1(2019)
• Page Start: 39
• Page End: 47
• Publication Date: 2019-01
• Subjects: Clinical medicine -- Periodicals; Medicine -- Research -- Periodicals; Medicine; Research -- United States; Clinical medicine; Medicine -- Research; Periodicals; 616.075
• DOI: 10.1136/jim-2018-000780
• Languages: English
• ISSNs: 1081-5589

Abstract

Multiple myeloma (MM) is characterized by the proliferation of malignant plasma cells and a subsequent overabundance of monoclonal paraproteins (M proteins). Everolimus works similarly to sirolimus as a mammalian target of rapamycin (mTOR) inhibitor. Bortezomib was the first therapeutic proteasome inhibitor to be tested in humans with MM. However, the combination of these two drugs for the treatment of MM has been rarely reported. In this study, we compared the therapeutic effects of everolimus and bortezomib, as well as those of a combination of everolimus and bortezomib, using an in vitro MM cell line model and in vivo xenograft mouse model. Our results showed that the synergistic antitumor effects of everolimus and bortezomib have significant inhibitory effect through inhibition of the AKT/mTOR pathway in both the MM cell lines and MM-bearing mice model. Our results provided evidence that the mTOR inhibitor, everolimus, will be a potential drug in MM therapy.